Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Alzheimer's Disease

Free Subscription 25.08.2025 1 Alzheimer Dis Assoc Disord 20 Alzheimers Dement 2 BMC Geriatr 1 BMC Neurol 1 Brain Res 1 Int J Neurosci 4 J Alzheimers Dis 1 J Biol Chem 1 J Neurochem 1 J Neurol 1 J Neurol Neurosurg Psychiatry 1 J Neurosci 1 JAMA 4 Lancet Neurol 3 Nat Med 1 Nat Ment Health 1 Nature 1 Neurobiol Dis 2 Neurochem Res 5 Neurology 1 Neuropsychology 1 Neurosci Lett 4 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Alzheimer Dis Assoc Disord

1. PEREIRA DA SILVA AM, Falcao Carneiro Filho L, Virgilio Ribeiro F, Rodrigues Menezes I, et al
   Efficacy, Immunogenicity, Safety, and Tolerability of AADvac1 in Alzheimer Disease: A Systematic Review and Meta-Analysis of Placebo-Controlled Trials.
   Alzheimer Dis Assoc Disord. 2025 Aug 18. doi: 10.1097/WAD.0000000000000686.
   PubMed         Abstract available
   
   

   
   Alzheimers Dement

2. DORFSMAN DA, Prough MB, Gulyayev AV, Caywood LJ, et al
   Linkage and association of preserved cognitive function in the midwestern Amish at a higher genetic risk of Alzheimer's disease.
   Alzheimers Dement. 2025;21:e70627.
   PubMed         Abstract available
   
   
3. KIM TH, Head E, Stark CEL, Sordo L, et al
   Late-life emergence of neuropsychiatric symptoms and risk of cognitive impairment in cognitively unimpaired individuals.
   Alzheimers Dement. 2025;21:e70619.
   PubMed         Abstract available
   
   
4. WOOD ALEXANDER M, Paterson J, Arvanitakis Z, Black SE, et al
   Cardiovascular contributions to dementia: Examining sex differences and female-specific factors.
   Alzheimers Dement. 2025;21:e70610.
   PubMed         Abstract available
   
   
5. WANG R, Maloney B, Beck JS, Counts SE, et al
   MicroRNA-153-3p targets repressor element 1-silencing transcription factor (REST) and neuronal differentiation: Implications for Alzheimer's disease.
   Alzheimers Dement. 2025;21:e70399.
   PubMed         Abstract available
   
   
6. POUDEL PC, Frost SM, Eslick S, Sohrabi HR, et al
   Ocular changes as potential biomarkers for early diagnosis of Alzheimer's disease.
   Alzheimers Dement. 2025;21:e70476.
   PubMed         Abstract available
   
   
7. LEONE R, Kobeleva X, Rowe B, Choupan J, et al
   Alterations in MRI-visible perivascular spaces precede dementia diagnosis by 18 years in autosomal dominant Alzheimer's disease.
   Alzheimers Dement. 2025;21:e70588.
   PubMed         Abstract available
   
   
8. PTOMEY L, Hom C, Wilkins H, Doran E, et al
   Alzheimer's Disease Research Center Down Syndrome Cores: Experience from two sites.
   Alzheimers Dement. 2025;21:e70612.
   PubMed         Abstract available
   
   
9. 
   Correction to "Genetic and pharmacologic enhancement of SUMO(2) conjugation prevents and reverses cognitive impairment and synaptotoxicity in a preclinical model of Alzheimer's disease".
   Alzheimers Dement. 2025;21:e70606.
   PubMed        
   
   
10. NOVOSELTSEVA A, Kureli G, Chang S, Yang J, et al
    Imaging myelin degradation in ex vivo prefrontal cortex tissue blocks in Alzheimer's disease and chronic traumatic encephalopathy.
    Alzheimers Dement. 2025;21:e70582.
    PubMed         Abstract available
    
    
11. SAVOLA S, Tuimala J, Kivisto V, Kero M, et al
    Hippocampal tau distribution in primary age-related tauopathy: The Vantaa 85+ Study.
    Alzheimers Dement. 2025;21:e70613.
    PubMed         Abstract available
    
    
12. DANHASH EP, Verbeck AC, Western D, Diaz-Pacheco AS, et al
    Ms4a4a deficiency ameliorates plaque pathology in a mouse model of amyloid accumulation.
    Alzheimers Dement. 2025;21:e70580.
    PubMed         Abstract available
    
    
13. HOWARD CW, Reich M, Luo L, Pacheco-Barrios N, et al
    Cognitive outcomes of deep brain stimulation depend on age and hippocampal connectivity in Parkinson's and Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70498.
    PubMed         Abstract available
    
    
14. AKGUN B, Gulyayev AV, Coker M, Hamilton-Nelson KL, et al
    ABCA7 deletion lowers age at onset of Alzheimer's disease and interacts with APOE epsilon4 synergistically in African-ancestry populations.
    Alzheimers Dement. 2025;21:e70583.
    PubMed         Abstract available
    
    
15. WRETLIND A, Xu J, Chen W, Velayudhan L, et al
    Lipid profiling reveals unsaturated lipid reduction in women with Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70512.
    PubMed         Abstract available
    
    
16. MARCATTI M, Tumurbaatar B, Zhang WR, Scaduto P, et al
    A brain-derived tau oligomer polymorph is associated with cognitive resilience to Alzheimer's disease.
    Alzheimers Dement. 2025;21:e70550.
    PubMed         Abstract available
    
    
17. SHWAB EK, Pathak GA, Harvey J, Belloy ME, et al
    Leveraging multiomic approaches to elucidate mechanisms of heterogeneity in Alzheimer's disease: Neuropsychiatric symptoms, co-pathologies, and sex differences.
    Alzheimers Dement. 2025;21:e70549.
    PubMed         Abstract available
    
    
18. WANG J, Wang ZY, Chen SF, Wang RZ, et al
    Role of (18)F-florzolotau PET in diagnostic and therapeutic decision-making for cognitive impairment.
    Alzheimers Dement. 2025;21:e70563.
    PubMed         Abstract available
    
    
19. AKINWANDE KS, Whitehead P, Diala S, Coker M, et al
    Developing biobanking processes for Alzheimer's disease and related dementia research in Africa: Experience from the Recruitment and Retention for Alzheimer's Disease Diversity in the Alzheimer's Disease Sequencing Project (READD-ADSP).
    Alzheimers Dement. 2025;21:e70559.
    PubMed         Abstract available
    
    
20. GRACNER T, Chaturvedi R, Nguyen P, Heun-Johnson H, et al
    The burden of cognitive impairment.
    Alzheimers Dement. 2025;21:e70436.
    PubMed         Abstract available
    
    
21. LIN RL, Sims SL, Wright NA, Galopin LB, et al
    Astrovascular decoupling in awake 5xFAD mice is associated with reduced astrocytic calcium.
    Alzheimers Dement. 2025;21:e70564.
    PubMed         Abstract available
    
    

    
    BMC Geriatr

22. JIANG X, Lv G, Franklin J, Li M, et al
    Causal effect of conventional anti-dementia drugs on economic burden: an orthogonal double/debiased machine learning approach.
    BMC Geriatr. 2025;25:659.
    PubMed         Abstract available
    
    
23. DE OLIVEIRA MPB, Calixtre LB, de Castro Cezar NO, Lima-Truax C, et al
    Reproducibility and validity of adapted clinical tests for the assessment of muscle strength in community-dwelling older adults living with Alzheimer's disease.
    BMC Geriatr. 2025;25:636.
    PubMed         Abstract available
    
    

    
    BMC Neurol

24. EBRAHIMI R, Mohammad Soltani S, Masouri MM, Seifi M, et al
    Glutamatergic and GABAergic metabolite levels in Alzheimer's disease: a systematic review and meta-analysis.
    BMC Neurol. 2025;25:344.
    PubMed         Abstract available
    
    

    
    Brain Res

25. HU X, Morihara R, Fukui Y, Bian Y, et al
    Spearmint extract Neumentix downregulates amyloid-beta accumulation by promoting phagocytosis in APP23 mice.
    Brain Res. 2025;1863:149752.
    PubMed         Abstract available
    
    

    
    Int J Neurosci

26. RIKOS D, Siokas V, Mentis AA, Aloizou AM, et al
    TREM2 R47H variant and risk for Alzheimer's disease: assessment in a Greek population and updated meta-analysis.
    Int J Neurosci. 2024;134:786-794.
    PubMed         Abstract available
    
    

    
    J Alzheimers Dis

27. JIANG C, Qi J, Zou H, Lopez O, et al
    Impact of antidiabetic therapy on cognitive function in patients with type 2 diabetes and Alzheimer's disease: A comprehensive analysis.
    J Alzheimers Dis. 2025 Aug 25:13872877251365662. doi: 10.1177/13872877251365662.
    PubMed         Abstract available
    
    
28. SAMPATH R, Baskar M
    Biomarker extraction-based Alzheimer's disease stage detection using optimized deep learning approach.
    J Alzheimers Dis. 2025 Aug 19:13872877251360394. doi: 10.1177/13872877251360394.
    PubMed         Abstract available
    
    
29. GIM J
    Revisiting APOE: Insights from rare variants and the expanding landscape of Alzheimer's disease genetics.
    J Alzheimers Dis. 2025 Aug 17:13872877251366662. doi: 10.1177/13872877251366662.
    PubMed         Abstract available
    
    
30. KONISHI K, Spets DS, Fisher P, Aroner S, et al
    Sex differences in the impact of genetic and clinical risk factors for Alzheimer's disease in midlife.
    J Alzheimers Dis. 2025 Aug 17:13872877251366701. doi: 10.1177/13872877251366701.
    PubMed         Abstract available
    
    

    
    J Biol Chem

31. ORMAZABAL P, Gherardelli C, Pinto C, Servili E, et al
    Andrographolide modulates glucose metabolism in visceral adipose tissue in an Alzheimer's disease obese mouse model.
    J Biol Chem. 2025 Aug 16:110607. doi: 10.1016/j.jbc.2025.110607.
    PubMed         Abstract available
    
    

    
    J Neurochem

32. TEIXEIRA LCR, Pereira JD, Mamede I, Caramelli P, et al
    Common miRNAs, Genes, and Regulatory Pathways in Alzheimer's Disease and Type 2 Diabetes Mellitus: An Integrative Analysis of Systematic Reviews, Bioinformatics and Data Mining.
    J Neurochem. 2025;169:e70196.
    PubMed         Abstract available
    
    

    
    J Neurol

33. MAZZEO S, Crucitti C, Lassi M, Ingannato A, et al
    The HTT gene influences plasma neurofilament light chain and brain metabolism in prodromal Alzheimer's disease.
    J Neurol. 2025;272:588.
    PubMed         Abstract available
    
    

    
    J Neurol Neurosurg Psychiatry

34. DE GIORGI R, Ghenciulescu A, Yotter C, Taquet M, et al
    Glucagon-like peptide-1 receptor agonists for major neurocognitive disorders.
    J Neurol Neurosurg Psychiatry. 2025;96:870-883.
    PubMed         Abstract available
    
    

    
    J Neurosci

35. WEISS BE, Gant JC, Lin RL, Gollihue JL, et al
    Disrupted calcium dynamics in reactive astrocytes occur with endfeet-arteriole decoupling in an amyloid mouse model of Alzheimer's disease.
    J Neurosci. 2025 Aug 15:e0349252025. doi: 10.1523/JNEUROSCI.0349-25.2025.
    PubMed         Abstract available
    
    

    
    JAMA

36. RUBIN R
    Treating Alzheimer Disease With Antiamyloid Therapies-The Real-World Experience Grows.
    JAMA. 2025 Aug 22. doi: 10.1001/jama.2025.14180.
    PubMed        
    
    

    
    Lancet Neurol

37. KESHAVAN A, Algeciras-Schimnich A
    Plasma phosphorylated tau for Alzheimer's disease diagnosis.
    Lancet Neurol. 2025;24:715-717.
    PubMed        
    
    
38. RYAN NS
    Alzheimer's disease in Down syndrome: progress and promise.
    Lancet Neurol. 2025;24:717-718.
    PubMed        
    
    
39. THERRIAULT J, Brum WS, Trudel L, Macedo AC, et al
    Blood phosphorylated tau for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.
    Lancet Neurol. 2025;24:740-752.
    PubMed         Abstract available
    
    
40. RAFII MS, Schlachetzki Z, Barroeta I, Head E, et al
    Down syndrome and Alzheimer's disease: insights into biomarkers, clinical symptoms, and pathology.
    Lancet Neurol. 2025;24:753-762.
    PubMed         Abstract available
    
    

    
    Nat Med

41. SHVETCOV A, Johnson ECB, Winchester LM, Walker KA, et al
    APOE epsilon4 carriers share immune-related proteomic changes across neurodegenerative diseases.
    Nat Med. 2025;31:2590-2601.
    PubMed         Abstract available
    
    
42. IMAM F, Saloner R, Vogel JW, Krish V, et al
    The Global Neurodegeneration Proteomics Consortium: biomarker and drug target discovery for common neurodegenerative diseases and aging.
    Nat Med. 2025;31:2556-2566.
    PubMed         Abstract available
    
    
43. OH HS, Le Guen Y, Rappoport N, Urey DY, et al
    Plasma proteomics links brain and immune system aging with healthspan and longevity.
    Nat Med. 2025;31:2703-2711.
    PubMed         Abstract available
    
    

    
    Nat Ment Health

44. DINIZ BS, Chen Z, Steffens DC, Pilling L, et al
    Proteogenomic signature of Alzheimer's disease and related dementia risk in individuals with major depressive disorder.
    Nat Ment Health. 2025;3:879-888.
    PubMed         Abstract available
    
    

    
    Nature

45. 
    Human brain organoids reveal new path for Alzheimer's drugs.
    Nature. 2025;644:845.
    PubMed        
    
    

    
    Neurobiol Dis

46. SANTIAGO J, Poceviciute D, Vogel J, Brinkmalm G, et al
    Retinal tau phosphorylation in Alzheimer's disease: A mass spectrometry study.
    Neurobiol Dis. 2025;215:107057.
    PubMed         Abstract available
    
    

    
    Neurochem Res

47. PARMAR P, Chauhan H, Modi P, Israni D, et al
    Pharmacological Evaluation and In-Silico Study of Sabinene as a Potential Anti-Alzheimer's Drug in AlCl(3)-Induced Rat Model via BACE-1 and GSK3beta Modulation.
    Neurochem Res. 2025;50:278.
    PubMed         Abstract available
    
    
48. WANG S, Xu Z, Wang S, Peng Q, et al
    Alamandine Rescues Cognitive Impairment and Ameliorates Alzheimer's Disease-Like Neuropathology in APP/PS1 Mice.
    Neurochem Res. 2025;50:277.
    PubMed         Abstract available
    
    

    
    Neurology

49. OVEISGHARAN S, Yu L, Yang J, Agrawal S, et al
    Cortical Gray Matter Proteins Associated With Cerebral Amyloid Angiopathy in Community-Dwelling Older Adults: An Autopsy Study.
    Neurology. 2025;105:e214024.
    PubMed         Abstract available
    
    
50. ONG JJH, Leow YJ, Qiu B, Tanato P, et al
    Association of Enlarged Perivascular Spaces With Early Serum and Neuroimaging Biomarkers of Alzheimer Disease Pathology.
    Neurology. 2025;105:e213836.
    PubMed         Abstract available
    
    
51. YIM S, Park S, Lim K, Kang H, et al
    Integrating MRI Volume and Plasma p-Tau217 for Amyloid Risk Stratification in Early-Stage Alzheimer Disease.
    Neurology. 2025;105:e213954.
    PubMed         Abstract available
    
    
52. KAPASI A, James BD, Yu L, Sood A, et al
    Mixed Pathologies and Cognitive Outcomes in Persons Considered for Anti-Amyloid Treatment Eligibility Assessment: A Community-Based Study.
    Neurology. 2025;105:e214004.
    PubMed         Abstract available
    
    
53. PETERSEN RC
    Alzheimer Disease Treatments and Co-Pathologies: But At What Age?
    Neurology. 2025;105:e214061.
    PubMed        
    
    

    
    Neuropsychology

54. BARVAS E, Mattavelli G, Guttmann S, Papagno C, et al
    Using the Modified Taylor Complex Figure-Recognition Trial (MTCF-RT) to differentiate amnestic patients with Alzheimer's disease from patients with memory deficits due to Parkinson's disease or subcortical ischemic vascular dementia.
    Neuropsychology. 2025 Aug 25. doi: 10.1037/neu0001036.
    PubMed         Abstract available
    
    

    
    Neurosci Lett

55. ZHANG T, E ED, Liu C, Li JW, et al
    Tropisetron modulates the firing activity of pyramidal and fast-spiking hippocampal CA1 neurons in a mouse model of Alzheimer's disease.
    Neurosci Lett. 2025 Aug 17:138360. doi: 10.1016/j.neulet.2025.138360.
    PubMed         Abstract available
    
    

    
    PLoS One

56. GOODLAND MN, Banerjee S, Niehoff ML, Young BJ, et al
    Cannabidiol improves learning and memory deficits and alleviates anxiety in 12-month-old SAMP8 mice.
    PLoS One. 2025;20:e0296586.
    PubMed         Abstract available
    
    
57. ALMARRI B
    Deep learning-based Alzheimer's disease detection using magnetic resonance imaging and gene expression data.
    PLoS One. 2025;20:e0330085.
    PubMed         Abstract available
    
    
58. SPENCER B, Marr RA, Gindi R, Potkar R, et al
    Correction: Peripheral Delivery of a CNS Targeted, Metalo-Protease Reduces Abeta Toxicity in a Mouse Model of Alzheimer's Disease.
    PLoS One. 2025;20:e0330647.
    PubMed         Abstract available
    
    
59. CAMPBELL-COUSINS A, Guazzo F, Bastin ME, Parra MA, et al
    Multiplex nodal modularity: A novel network metric for the regional analysis of amnestic mild cognitive impairment during a working memory binding task.
    PLoS One. 2025;20:e0328736.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Alzheimer's Disease is free of charge.